Data visualisation application speeds lead discovery

Published: 31-Aug-2010
Manufacturing Research & Development

Merck Millipore has new software for visualising GPCR and kinase activity

The Life Science division of Merck KGaA, Merck Millipore has introduced a software application for visualising GPCR (G-protein coupled receptors), as well as kinase activity.

The new Data Analysis and Report Tool (DART) creates an interactive map of target profiling assay results and enables drug researchers to make faster, more informed decisions.

‘Lead profiling often requires sifting through hundreds or even thousands of data points to pinpoint targets for further optimization studies,’ said Paul Wilhite, senior manager of eBusiness at Merck Millipore. ‘This new online tool provides a unique, information-rich interface so scientists can rapidly narrow their research and effectively collaborate with colleagues.’

The application projects each compound's activity profile onto a map depicting clusters of target protein families. This map provides scientists with immediate graphical insight into cross-target interactions to help drive structure-activity relationship (SAR) studies. The application is fully customisable. Data limits, sizing, colours, and target subclasses can be adjusted in seconds, thereby turning numerical data into a graphical display that can highlight biologically significant conclusions. Additionally, selected target information is dynamically populated and includes the gene symbol and aliases; links to bioinformatics content and recent publications; as well as links to appropriate Merck Millipore products.

Users of Merck Millipore's KinaseProfiler and GPCRProfiler screening services can upload their data directly into the DART tool or enter other datasets manually to take advantage of the software's analytical power and presentation-quality images.

See more

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Read more
Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells

Trending Articles

  1. LYOVAC® ECO Mode: making pharmaceutical freeze-drying leaner and greener Following the recent announcement that GEA Lyophil has received third-party certification for the energy-saving credentials of its innovative algorithm for freeze-drying applications, Dr Kevin Robinson caught up with Senior Director of Lyophilization Technology Management, Thomas Beutler, to find out more
  2. Marchesini Group and AST announce strategic partnership to strengthen aseptic production capacity and expand global market presence Marchesini Group, a leader in pharmaceutical packaging machinery, and AST, a US leader in the drug product manufacturing industry, have entered a strategic partnership that combines the expertise, technologies, and global reach of two highly respected industry leaders
  3. Biotech Fluidics AB At Biotech Fluidics, our aim is to help you make your analytical work more effective and reliable.
  4. Domino’s Adem Kulauzovic appointed to the Board of OMAC Domino’s Adem Kulauzovic appointed to the Board of OMAC to help shape the future of packaging automation
  5. Piramal Pharma Solutionsd demonstrates commitment to excellence with net promoter score Piramal Pharma Solutions recently achieved a net promoter score (NPS) of 55, far surpassing industry averages

Upcoming event

From powder to granules: a deep dive into wet granulation methods

14 January 2026 | Virtual See all

You may also like

Research & Development

Med Uni Graz researchers present a new approach to targeted therapy for leukaemia

Acute myeloid leukaemia (AML) is a cancer of the haematopoietic cells that causes the uncontrolled proliferation of certain immature blood cells
Manufacturing

When science meets security: the future of small molecule outsourcing

Looking across 2025 and into 2026, chemical and pharmaceutical manufacturing is navigating a period of rapid transition, with trends emerging that will influence competitiveness for years to come
Research & Development

Research shows that Pepaxti is effective in high-risk myeloma

Oncopeptides announces new research demonstrating that Pepaxti (melflufen) maintains its anti-myeloma activity in patients with high-risk genetic features, including deletion 17p (del(17p)) and TP53 mutations
Research & Development

Biologics at a turning point: complexity, AI and the road to 2026

Despite rapid change, the growing complexity of biologics and the rise of AI-driven design are reinforcing the increasing need for deep scientific expertise and innovation leadership, says Campbell Bunce (CB), Chief Scientific Officer at Abzena
Manufacturing

The story of an East-West German company | 150 years of Romaco Kilian

Kilian’s story tells of the rise, fall and resurgence of a Berlin company steeped in tradition, which is now based in Cologne. It is the story of the entrepreneur Fritz Kilian, who turned a small locksmith’s workshop in Berlin into a successful company that is still a leading manufacturer of tablet presses today. It is the story of a visionary whose legacy has endured the test of time and continues to this day
Manufacturing

Dual stage degasser vacuum pump from Biotech Fluidics

Biotech Fluidics has introduced a durable dual stage moulded vacuum pump designed to improve your fluidic degassing experience
Manufacturing

Thermo Fisher Scientific Expands Gibco Bacto portfolio

Its next-generation, chemically defined media will boost E. coli biomanufacturing productivity, helping innovators scale plasmid DNA and protein production with confidence
Subscribe now